Navigation Links
Oxygen Biotherapeutics, Inc. Receives Letter From FDA Outlining Path Forward to Resume Oxycyte Clinical Trials in TBI in U.S.A.
Date:3/19/2009

Company Expands Overseas TBI Trial

COSTA MESA, Calif., March 19 /PRNewswire-FirstCall/ -- Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) today announced that the company has received a letter from the FDA that outlines what the agency termed a "path forward" as a basis to resume clinical studies of Oxycyte(R) in TBI. Oxycyte is the company's perfluorocarbon (PFC) therapeutic oxygen carrier.

The letter was in response to the company's request for formal dispute resolution that was submitted to the FDA Ombudsman's office. As a result, the Office of Blood Research and Review examined the reviewing division's decision to delay the start of a proposed Phase II dose escalation study of Oxycyte in traumatic brain injury (TBI).

"This outcome of the review is of great relief to us," said Chris J. Stern, company chairman and CEO. "It is helpful because it now positions the FDA to participate with the company in the development of the recommended experimental protocols to ensure their alignment with the agency's suggested path forward. This gives us the best chance to demonstrate safety of Oxycyte sufficient to move ahead in TBI in the United States," said Stern.

"In the meantime, we are moving ahead with our planned dose-escalation TBI study outside the U.S. We have expanded the trial to now include up to six sites in Switzerland and we will announce another country soon. This approach will put us on what we see as the best and fastest track for Oxycyte's clinical development while meeting the needs of all our stakeholders."

About Oxygen Biotherapeutics, Inc.

Oxygen Biotherapeutics, Inc. is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and continuous substrate monitoring. The company has under development a perfluorocarbon therapeutic oxygen carrier and liquid ventilation product (Oxycyte(R)) and an im
'/>"/>

SOURCE Oxygen Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Battelle Scientists Named on Patent for Making Oxygen From Light and Water
2. Northfield Laboratories Inc. Presentation at FDA/NIH Workshop on Hemoglobin-Based Oxygen Carriers
3. Oxygen Relieves IBS and Constipation Symptoms in New Clinical Studies
4. Alliance Pharmaceutical Corp. Updates Oxygent(TM) Clinical Development Plan
5. Quest Diagnostics ClariSure(TM) Postnatal Molecular Test Receives Clinical Laboratory Approval from New York State
6. Lake Hospital System Receives $60,000 Grant for Groundbreaking Music Therapy Study
7. CSL Behring Receives Orphan-Drug Exclusivity for RiaSTAP(TM), First and Only Approved Treatment of Acute Bleeding Episodes in Patients with Congenital Fibrinogen Deficiency
8. Childrens Hospital Receives $6.7 Million Grant From Gates Foundation to Study Influenza Vaccine in Pregnant Women in Asia
9. deCODE Receives California Clinical Laboratory License
10. Omeros Receives $3.1 Million Milestone Payment from The Stanley Medical Research Institute for Schizophrenia Program
11. Phico Therapeutics Receives GBP1 Million Award From the Wellcome Trust to Take Anti-MRSA Nasal Product Through Early Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... 2015  CipherHealth, a leading provider of innovations and ... sent representatives to the Nepalese American Nursing Association to ... nurses to Nepal to aid ... month. In addition to helping fund the travel costs ... for much-needed medical supplies for the mission.  ...
(Date:5/5/2015)... 2015   InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" ... today that it will release its full financial results for ... 11 th before the open, followed by a conference ... and business outlook. Participants should call (888) 243-4451 ... and request the InspireMD call. A live webcast of the ...
(Date:5/5/2015)... 5, 2015  Trovagene, Inc. (NASDAQ:  TROV), a ... financial results for the three months ended March ... quarter, we presented favorable clinical results at ASCO ... demonstrating our Precision Cancer Monitoring platform,s ability to ... and lung cancers," said Antonius Schuh, Ph.D., chief ...
Breaking Medicine Technology:Five Nurses and Medical Supplies En Route to Nepal With Donation Assistance from CipherHealth 2InspireMD to Report Financial Results for the First Quarter Ended March 31, 2015 on Monday, May 11th 2InspireMD to Report Financial Results for the First Quarter Ended March 31, 2015 on Monday, May 11th 3Trovagene, Inc. Announces First Quarter 2015 Financial Results 2Trovagene, Inc. Announces First Quarter 2015 Financial Results 3Trovagene, Inc. Announces First Quarter 2015 Financial Results 4Trovagene, Inc. Announces First Quarter 2015 Financial Results 5Trovagene, Inc. Announces First Quarter 2015 Financial Results 6
... 15, 2011 The U.S. Food and Drug Administration approved ... patients undergoing magnetic resonance imaging (MRI) of the central ... Gadavist was approved by the FDA on March ... system, helping to detect and visualize lesions that disrupt ...
... and ALISO VIEJO, Calif., March 15, 2011 ... disease screening, cell/molecular biology and immunological testing for ... an agreement with Ambry Genetics, a global leader ... healthcare and life sciences industries, that will allow ...
Cached Medicine Technology:FDA Approves Gadavist for Central Nervous System Scans 2LABS, Inc. Announces Alliance with Ambry Genetics to Expand Testing Solutions for the Reproductive Health Industry 2
(Date:5/5/2015)... Atlanta, Georgia (PRWEB) May 05, 2015 ... Software of Victoria BC announced the Skedans Sensor ... The platform, for mobile and web app developers, provides ... from airborne and mobile sensors. , The Skedans Sensor ... at the intersection of the Internet of Things, Web ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 This year, ... Medals, four Special Merit Awards, three Gold Medals and ... projects are described as follows: , (1) Grand Prize ... Robotic Mannequin for Fashion Design and Fitting, Principal Investigator: ... , The apparel industry relies very much on the ...
(Date:5/5/2015)... New York, NY (PRWEB) May 05, 2015 ... Marketing Platform that enables businesses to deploy Mobile Engagement ... Constant Contact . ProTexting clients can now leverage ... Marketing reach by collecting and syncing subscribers’ e-mail addresses ... Kassabov says “We have recognized that the growing trend ...
(Date:5/5/2015)... 2015 Rare Genomics Institute ... study aimed at determining how crowdfunding can promote scientific ... international non-profit providing rare disease patients with access to ... scientists and researchers, and help for payment of these ... excited to see how crowdfunding will not only help ...
(Date:5/5/2015)... 2015 On April 8th, 2015, at ... Choices Recovery sponsored Durkin Entertainment’s “RockNRolla” EcoLuxe Lounge, a ... of sustainable product placement in TV and film. ... providers of ecologically sound and socially conscious products and ... event that makes appearances at various awards ceremonies and ...
Breaking Medicine News(10 mins):Health News:Skedans Systems Announces Skedans Sensor Collaboration Platform at AUVSI's Unmanned Systems 2015 in Atlanta 2Health News:PolyU wins top prizes in Geneva’s Invention Expo 2Health News:PolyU wins top prizes in Geneva’s Invention Expo 3Health News:PolyU wins top prizes in Geneva’s Invention Expo 4Health News:PolyU wins top prizes in Geneva’s Invention Expo 5Health News:ProTexting SMS Mobile Marketing platform integrates with Constant Contact 2Health News:ProTexting SMS Mobile Marketing platform integrates with Constant Contact 3Health News:Rare Genomics Institute to Study Impact of Crowdfunding on Rare Diseases 2Health News:Choices Recovery Mishawaka Talks About Overcoming Adversity with Actor Matthew Ziff at the “RockNRolla Movie Awards” EcoLuxe Lounge 2
... Focus is system that regulates blood pressure and fluid ... News) -- New research is shedding some light on ... cause miscarriage and death in pregnant women. , "Preeclampsia ... 10 percent of all pregnancies in the United States," ...
... (FA) is a rare and dangerous disease, new laboratory research ... shows it may lead researchers toward clues in more common ... a study published in the Sept. 11 issue of the ... proteins to DNA damage sites is controlled by replication in ...
... the biggest student drinking problems have so far failed to turn ... in the September issue of the Journal of Studies on ... students, alcohol habits showed little change over a dozen years. In ... two weeks; in 2005, 56 percent said the same. And although ...
... blind and visually impaired often rely on others to provide ... with this method is that it doesn,t give them the ... Lahav of Tel Aviv University,s School of Education and Porter ... to the blind, Dr. Lahav has invented a new software ...
... Administration,s (FDA) recent decision to approve the radioimmunotherapy (RIT) ... lymphoma (NHL). "This is welcome news for ... Ph.D., president of SNM and director of nuclear medicine ... "We,ve known for some time that RIT works extremely ...
... Television journalist Veronica ... and now directs her brother,s story to the White House , ... Los Angeles, CA (PRWeb) September 10, 2009 -- After ... brought the tale of her brother Eric,s tragic battle against health care red tape to ...
Cached Medicine News:Health News:Research Seeks Cause of Preeclampsia 2Health News:Replication at DNA damage sites highlights Fanconi anemia and breast cancer proteins 2Health News:Heavy-drinking colleges showing no improvements 2Health News:Virtual maps for the blind 2Health News:Virtual maps for the blind 3Health News:SNM applauds FDA's decision to approve Zevalin 2Health News:Television Journalist Veronica De La Cruz Brings Her Brother's Story from L.A. to White House in Fight for Health Care Reform 2Health News:Television Journalist Veronica De La Cruz Brings Her Brother's Story from L.A. to White House in Fight for Health Care Reform 3
... EndoProbe handpieces, used ... the ophthamologist with uncompromised ... pathologies. EndoProbe handpieces ... Medical OcuLight green (532 ...
... integrated custom assay service that develops assays for ... of interest, the customer simply provides the samples ... provide a protocol and a Field Applications Specialist ... the laboratory. This will help reduce labor costs ...
... The Medical Imaging Consultant, PDA Edition ... fellows who may order diagnostic imaging studies. ... device to extensive information that will help ... based on symptoms, and which studies will ...
The Perkins has been established for well over 20 years as a "world standard" for hand held applanation tonometers....
Medicine Products: